Opinion|Videos|February 13, 2026
Exploring Targeted Strategies in Early-Stage EGFR+ NSCLC
Subcutaneous amivantamab offers significant advantages over IV administration, including reduced infusion reactions and quicker patient turnover in clinics.
Advertisement
Episodes in this series
Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, FACP, FASCO, turn to the evolving role of targeted therapy in earlier-stage EGFR-mutated NSCLC. They outline ongoing research evaluating EGFR-directed approaches in the adjuvant and perioperative settings. The discussion highlights how these strategies may shift treatment paradigms beyond metastatic disease.
Advertisement
Related to this article
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Sonrotoclax monotherapy produced durable responses in Chinese patients with relapsed/refractory mantle cell lymphoma.
lan M. Thompson Jr., MD, discusses the potential role of 5-ARIs for the treatment of patients with prostate cancer.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
UCSF Health’s Adam Blaisdell, MD, PhD, has been selected as an IGNITE fellow by the Cancer Research Institute.
BI-1808 combined with pembrolizumab elicited a 24% confirmed overall response rate in heavily pretreated, platinum-resistant recurrent ovarian cancer.
Eric K. Singhi, MD, and Kyle G. Mitchell, MD, MSc, discuss the present and future role of LCT in NSCLC.
Mariana C. Stern, PhD, discusses the biggest gaps identified in the 2026 AACR Disparities Progress Report and what oncologists can do to combat them.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
2
Exploring the Rationale for 5-Alpha Reductase Inhibitors in Prostate Cancer Prevention and Active Surveillance
3
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
4
Dostarlimab Monotherapy Elicits Responses in First-Line PD-L1-Positive HNSCC
5